Clinical trials: Transfusions
Transfusion Related Complication, Wrong Blood in Tube
Proficiency Based Training to Investigate WBIT
Incorrect labelling of blood samples occurs at a rate of 1% in the general laboratories and 6% in Blood Transfusion Laboratories.
- Trial name
- NCT03476005
- Testing
- proficiency based progression training
- Where
- Ireland
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Patrick Henn
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myeloid, Acute
Memory T-cell Infusion to Improve Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantation
The stud will evaluate whether infusions of CD45RA-depleted lymphocytes from the donor early post-transplant is a safe way to improve immunity to common infections in recipients of TCR-alpha/beta depleted hematopoietic stem cell…
- Conditions
- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myeloid, Acute, Immune Deficiency Disease, Bone Marrow Failure Syndromes
- Trial name
- 45RA_NEG_DLI (NCT02337595)
- Testing
- CD45RA-depleted peripheral blood mononuclear cells
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Thrombocytopenia
Effects of a Platelet Transfusion Best Practices Alert
This study is to determine the effectiveness of a computerized clinical decision support tool (Best Practice Alert - BPA) in reducing unnecessary platelet transfusions based on guidelines published by national transfusion…
- Trial name
- NCT04155775
- Testing
- Computer electronic health record alert (Best Practice Alert - BPA)
- Where
- United States
- Volunteers
- 446 people
- Sponsor
- Stanford University
Transfusion Reaction, Hemolytic
Challenge Transfusion of INTERCEPT Pathogen Reduced Red Blood Cells (RBCs) in Subjects With or Without Pre-existing Antibodies to INTERCEPT RBCs
This study aims to determine whether transfusion of INTERCEPT RBCs into patients with pre-existing antibodies to INTERCEPT RBCs will result in increased antibody titer indicative of a secondary immune response, and whether these…
- Trial name
- Challenge (NCT07152379)
- Testing
- 30-40 mL of INTERCEPT RBCs, ~30 mL of INTERCEPT RBCs plus plus 10 mL biotinylated INTERCEPT RBCs
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Cerus Corporation
Premature Infant, Umbilical Cord
Umbilical Cord Milking vs Delayed Cord Clamping in Preterm Infants Born by Cesarean Section
The purpose of this study is to determine whether the umbilical cord milking in preterm infants born by cesarian section less than 34 weeks is more effective than delayed cord clamping to obtain higher levels of hemoglobin.
- Conditions
- Premature Infant, Umbilical Cord, Milking, Delayed Clamping
- Trial name
- NCT02187510
- Testing
- Umbilical cord milking, Delayed cord clamping
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Corporacion Parc Tauli
Infant, Extremely Premature, Erythrocyte Transfusion
Red Blood Cells From Umbilical Cord for Transfusion of Preterm Infants
This study has been designed to demonstrate that red blood cell from umbilical cord blood (UCB-RBC) is a safe and available product for extremely preterm infants (EPI) transfusion and that transfusion of UCB-RBC is non-less…
- Conditions
- Infant, Extremely Premature, Erythrocyte Transfusion, Umbilical Cord Issue
- Trial name
- NCT05612919
- Testing
- Red blood cell from umbilical cord blood, Red blood cell from adult donor
- Where
- Spain
- Volunteers
- 41 people
- Sponsor
- Hospital Clinic of Barcelona
β-thalassemia, Ineffective Erythropoiesis
Safety Study for Beta Thalassemia Subjects on PTG-300
In this study will investigate long term safety and use of the PTG-300 in Beta Thalassemia patients.
- Trial name
- TRANSCEND (NCT04054921)
- Testing
- PTG-300
- Where
- 16 sites in United States, Greece and 6 more
- Volunteers
- 34 people
- Sponsor
- Protagonist Therapeutics, Inc.
Fetomaternal Hemorrhage, Neonatal Anemia
Identification of Early Predictors of Fetomaternal Hemorrhage
Objectives: 1) To determine risk factors for fetomaternal hemorrhage. 2) To identify a cost-effective method to detect fetomaternal hemorrhage prior to significant fetal anemia.
- Trial name
- NCT01232387
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Transfusion Related Complication, Premature
Warmed Blood Transfusion in Premature Infants
Premature babies have to deal with many problems from the moment they are born due to the immature of their organs. Their clinical condition is unstable, especially in the first few weeks, and they are greatly affected by…
- Trial name
- NCT06425783
- Testing
- Warmed Blood Transfusion
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people
- Sponsor
- Goztepe Prof Dr Suleyman Yalcın City Hospital
Veinous, Chemotherapy
A Retrospective, Observational, Multicenter Study to Evaluate the Safety and Performance of POLYSITE® and SEESITE® Implantable Ports
The purpose of this study is to evaluate performance and safety of POLYSITE® and SEESITE® implantable ports allowing repeated and prolonged access to the venous system for the administration of chemotherapy, antibiotics…
- Conditions
- Veinous, Chemotherapy, Antibiotics, Antiviral Drugs
- Trial name
- NCT05519761
- Testing
- Implantation of veinous access ports
- Where
- 3 sites in France
- Volunteers
- 250 people
- Sponsor
- Perouse Medical
Infant, Low Birth Weight, Anemia
Erythropoietin Treatment in Extremely Low Birth Weight Infants
Objective: To investigate whether recombinant EPO reduces the need for transfusion in extremely low birth weight (ELBW) infants and to determine the optimal time for treatment.
- Trial name
- EPO (NCT00593801)
- Testing
- epoetin beta
- Where
- Germany
- Volunteers
- 219 people
- Sponsor
- Charite University, Berlin, Germany
Severe Malaria, Thrombocytopenia
Platelet-Directed Whole Blood Transfusion Strategy for Malaria
Open-label randomized controlled trial to test the effectiveness of whole blood transfusion for improving survival in children with severe malaria complicated by thrombocytopenia.
- Trial name
- PLATFORM (NCT05711485)
- Testing
- Whole blood transfusion
- Where
- 2 sites in United States, Zambia
- Volunteers
- 132 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Leukemia
A Feasibility Study of Prophylactic White Blood Cell Transfusions
Patients with leukemia often have low white blood cell counts after chemotherapy, which puts them at greater risk of infection. The standard of care for preventing infections is to give these patients antibiotic, antifungal, and…
- Trial name
- NCT01932710
- Testing
- White Blood Cell Transfusion
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- M.D. Anderson Cancer Center
Neonatal Hyperbilirubinemia
Clinical and Developmental Outcomes of Babies Who Became Yellow in the First Month of Life
The Shoklo Malaria Research Unit (SMRU) provides care to refugees and migrant populations along the Thai-Burma border since 1986.
- Trial name
- NCT02927093
- Volunteers
- 78 people
- Sponsor
- University of Oxford
Transfusion Related Complication
Effects of Therapeutic Plasmaexhange on Viscoelastic Tests in Non-coagulopathic Patients
Therapeutic plasma exchange is widely performed in patients with autoimmune disease. The exact effects of fresh frozen plasma on coagulation in this group of patients remains unknown.
- Trial name
- NCT04513249
- Testing
- dynamics of coagulation parameters
- Where
- Romania
- Volunteers
- 25 people
- Sponsor
- Institutul Clinic Fundeni
Anemia, Blood Transfusions, Autologous
A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Facilitating the Presurgical Collection of Blood to be Used for Self-donation During Surgery on the Spine, Hip, or Knee.
The purpose of this study is to evaluate the safety and effectiveness of epoetin alfa at doses of 150, 300, or 600 units per kilogram of body weight versus placebo in facilitating presurgical collection of blood for self-donation…
- Conditions
- Anemia, Blood Transfusions, Autologous, Orthopedic Procedures
- Trial name
- NCT00270140
- Testing
- epoetin alfa
- Volunteers
- 17 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Iron Overload
MRI T2* Mapping of Myocardium, Liver, Pancreas and Pituitary Gland
All patients were investigated using a 3T MRI and 1,5 T MRI scanners. For myocardium, pancreas and pituitary gland iron overload quantification in children we have used special sequences for T2*-mapping.
- Trial name
- NCT04835285
- Testing
- Npf.
- Where
- Russia
- Volunteers
- 152 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Erythroblastosis, Fetal, Erythroblastosis Fetalis, Rh Disease
EPO-4-Rhesus Study
Up to 80% of infants with hemolytic disease due to maternal alloimmunization, treated with IUT, require at least one top-up transfusion for late anemia during the first 3 months of life.
- Conditions
- Erythroblastosis, Fetal, Erythroblastosis Fetalis, Rh Disease, Erythroblastosis Fetalis Due to RH Antibodies, Erythroblastosis Fetalis Due to Isoimmunization
- Trial name
- EPO-4-Rhesus (NCT03104426)
- Testing
- Darbepoetin Alfa
- Where
- Netherlands
- Volunteers
- 42 people
- Sponsor
- Sanquin-LUMC J.J van Rood Center for Clinical Transfusion Research
Beta-Thalassemia
A Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Patients With Transfusion-Dependent Beta Thalassemia
This study is a Phase 2 multicenter, randomized, open-label, parallel-group study. The primary objective of the study is to evaluate the effect of LJPC-401 (synthetic human hepcidin) on iron levels in patients with…
- Trial name
- NCT03381833
- Testing
- LJPC-401
- Where
- 22 sites in United States, Australia and 6 more
- Volunteers
- 84 people
- Sponsor
- La Jolla Pharmaceutical Company
Myeloid Malignancy, Bone Marrow Failure Syndrome
Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation
The purpose of this study is to find out what effects, good and/or bad, the addition of clofarabine, a new chemotherapy agent, to a standard busulfan and fludarabine conditioning treatment has.
- Conditions
- Myeloid Malignancy, Bone Marrow Failure Syndrome, Transfusion-dependent Red Blood Cell (RBC) Defect, Congenital Immunodeficiency
- Trial name
- NCT01596699
- Testing
- Alemtuzumab, Busulfan, Fludarabine
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of California, San Francisco